In September 2020, the ACI created a consortium of members to submit a ‘super-dossier’ on their behalf
The UK has introduced regulation to establish a market for safe, orally-consumed legal cannabis extracts. The Food Standards Agency has developed a public list of cannabinoid (CBD) products permitted for sale to consumers. Publication of the list – a key stage on the path to full authorisation – is expected in 2023, following two years of co-operation between the FSA and the Association for the Cannabinoid Industry (ACI), the UK’s CBD sector trade body.
Only those products featured on the list have been given the green light by the FSA to stay on the market, in line with the UK requirements. Products not included must now be removed from shelves.
Steve Moore, ACI founder, commented: “The FSA public list represents a major milestone for the UK’s CBD category. It demonstrates the progress the sector has made to meet compliance requirements and creates greater regulatory certainty which, in turn, will increase levels of consumer trust, encourage investment in the sector, and promote innovation. ACI is immensely grateful for the work that our members and the FSA have put in to take this momentous step.”
Products on the list have undergone a novel food assessment, which was open to any CBD product designed for oral consumption on sale in the UK on or before 13 February 2020, with the deadline for applications set at 31 March 2021.
In September 2020, the ACI created a consortium of members to submit a ‘super-dossier’ on their behalf. This was lodged with the FSA in February 2021, and has helped members' products be placed on the public list. These products will, therefore, remain on the market as they progress towards validation and then authorisation. ACI has concluded the live phase of the OECD toxicology study required to validate dossiers. Data analysis is expected to be completed in June.
Moore said: “We are hugely proud that, through our consortium study, all members of the ACI have been included on the FSA’s public list, therefore earning the right to continue to be sold within the UK.”
Moore said ACI was keen to support CBD businesses that had failed to make it onto the list. “At this moment in time, we understand that, for some CBD businesses, the news will not be positive, and we openly invite those businesses to contact us at ACI to understand their next steps within this fledgling and rapidly growing market. We are here to support this industry and its community to thrive.”The FSA list covers products sold in England and Wales. CBD products on sale north of the border are subject to a separate authorisation process managed by Food Standards Scotland. In Northern Ireland, meanwhile, companies must continue to adhere to EU Novel Food rules and procedures as a result of Brexit protocols. Products designed to be inhaled, such as vapes, or applied to the skin, including cosmetics and massage oils, do not fall under the FSA’s remit. These were not assessed and will not appear on the list.